Results 181 to 190 of about 69,866 (217)

Biochemical profiling and symptomatology of androgen deficiency in males with cluster headache: A prospective case–control study

Headache: The Journal of Head and Face Pain, EarlyView.
Abstract Objectives/Background Cluster headache (CH) has historically been considered a male‐dominated disorder, suggesting a role for androgens in its pathophysiology. We aimed to evaluate hormone profiles and symptoms of androgen deficiency in CH.
Willemijn C. Naber, Roemer B. Brandt, Mariël Leon Morales‐Grooters, Ronald van der Wal, Sjoerd A. A. van den Berg, Jelle J. Goeman, Antoinette Maassen van den Brink, Rolf Fronczek   +7 more
wiley   +1 more source

The association between parental migraine, infantile colic, and later migraine in childhood: A scoping review of current evidence

Headache: The Journal of Head and Face Pain, EarlyView.
Abstract Background Evidence suggests that infantile colic, a common condition in early infancy, shares pathophysiological features with migraine. Objective Aim was to examine the current evidence on the association between infantile colic and migraine, focusing on both maternal migraine as a risk factor for infantile colic and infantile colic as a ...
Bella Poutanen, Ilari Kuitunen
wiley   +1 more source

Aseptic meningitis due to intravenous immunoglobulin therapy (IVIG) in therapy‐refractory pyoderma gangraenosum

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Katharina A. Kälber, Knut Schäkel, Alexander Enk, Julia K. Winkler   +3 more
wiley   +1 more source

Early improvements in function with atogepant as assessed by the Activity Impairment in Migraine–Diary: Post hoc analyses of three randomized, phase 3 clinical trials of atogepant for the preventive treatment of migraine

Headache: The Journal of Head and Face Pain, EarlyView.
Abstract Objective Evaluate early functional improvements with the preventive migraine treatment atogepant using Activity Impairment in Migraine–Diary (AIM‐D) individual and activity limitation items, and complete improvement in AIM‐D Performance of Daily Activities (PDA) and Physical Impairment (PI) domain scores assessed weekly during the first 4 ...
Richard B. Lipton, Pranav Gandhi, Andreas R. Gantenbein, Brett Dabruzzo, Karen Carr, Jonathan Stokes, Molly Duan, Rashmi B. Halker Singh, Hsiangkuo Yuan, Dawn C. Buse   +9 more
wiley   +1 more source

Real-world study of adverse events associated with triptan use in migraine treatment based on the U.S. Food and Drug Administration (FDA) adverse event reporting system (FAERS) database. [PDF]

J Headache Pain
Liu WH, Hu HM, Li C, Shi Q, Liu CH, Liu AX, Li YF, Zhang Y, Mao P, Fan BF.   +9 more
europepmc   +1 more source

Successful Management of Persistent DRESS with Tofacitinib: Two Case Reports

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Marc Hernández‐Santacana, Ignasi Martí‐Martí, Victoria Amat‐Samaranch, Irene Fuertes de Vega, Priscila Giavedoni, José M. Mascaró Jr   +5 more
wiley   +1 more source

Plasma amylin levels in migraine and after erenumab treatment: A REFORM study

Headache: The Journal of Head and Face Pain, EarlyView.
Plain Language Summary Researchers are searching for blood tests that can show what is happening in migraine and help predict who will benefit from preventive treatment, and blood amylin (a signaling molecule known to trigger migraine) has been shown to be elevated in people with chronic migraine.
Rogelio Domínguez‐Moreno, Tyla I. Alexander, William K. Karlsson, Haidar M. Al‐Khazali, Michael L. Garelja, Rune H. Christensen, Messoud Ashina, Debbie L. Hay, Håkan Ashina   +8 more
wiley   +1 more source

Real-world study of adverse events associated with gepant use in migraine treatment based on the VigiAccess and U.S. Food and Drug Administration's adverse event reporting system databases. [PDF]

Front Pharmacol
Liang Q, Liao X, Wu H, Huang Y, Liang T, Li H.   +5 more
europepmc   +1 more source

Novel targets in headache: A narrative review

Headache: The Journal of Head and Face Pain, EarlyView.
Abstract Objectives/Background This narrative review summarizes novel applications for the use of calcitonin gene‐related peptide (CGRP)‐targeted therapies that go beyond migraine, the latest updates with respect to targeting pituitary adenylate cyclase‐activating peptide (PACAP) as therapeutic in migraine, as well as exploring other more recently ...
Adriana Della Pietra, Peter J. Goadsby, Carolina Oldoni, Stephen Silberstein, Fred Cohen, Simon Akerman   +5 more
wiley   +1 more source

Building the evidence base for pediatric vertigo guidelines

Developmental Medicine &Child Neurology, EarlyView.
Joshua Gurberg
wiley   +1 more source